MAPK3 and cancer: In conclusion, the network pharmacology of this study was used to screen out the active compounds of SBG (baicalein and wogonin), 41 intersection targets (VEGFA, IL6, MAPK3, JUN, TNF, and other targets), and 20 main pathways (Pathways in cancer, IL-17, TNF signaling pathway and others).